December 3, 2009 (FinancialWire) — PuraMed BioScience (OTCBB: PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic, has recently secured funding through a private placement in the amount of $500,000, the largest amount to date, which will allow the company to initiate further efforts to reach its goals and objectives as outlined in its business plan.

This funding has enabled PuraMed BioScience to purchase air time for the company’s first direct response television commercial, expected to begin airing within the coming weeks in select test markets. The funding will also be allocated for several business activities that will further demonstrate the effectiveness and marketability of the LipiGesic series of products.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). The most recently issued reports and/or recorded webcasts include Cascade Corp. (NYSE: CASC), Anadarko Petroleum Corp. (NYSE: APC), Baytex Energy Trust (NYSE: BTE) (TSX: BTE), H & Q Healthcare Investors (NYSE: HQH), H & Q Life Science Investors (NYSE: HQL), PIMCO (NYSE: PYN) (NYSE: PMX) (NYSE: PZC), PIMCO Global StocksPLUS & Income Fund (NYSE: PGP), Taiwan Greater China Fund (NYSE: TFC) and Wolseley PLC (OTC: WOSCF) (London Stock Exchange: WOS).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.